Oppenheimer raised its price target on CME Group Inc. (NASDAQ:CME) to $300 from $282, maintaining an Outperform rating, as ...

Oppenheimer raised its price target on Netflix (NASDAQ: NFLX) to $1,425 from $1,200 on Thursday, while maintaining an Outperform rating on the streaming giant’s stock.The company, currently ...

Oppenheimer lowered its price target on Clearwater Analytics Holdings (NYSE:CWAN) stock to $36.00 from $40.00 on Wednesday while maintaining an Outperform rating. The company, currently trading at ...

Oppenheimer maintained its Outperform rating on Trevi Therapeutics, Inc. (NASDAQ: TRVI) shares and lifted the price target ...

Oppenheimer recently raised the price target on Analog Devices, Inc. (NASDAQ:ADI) to $265 from $225 and kept an Outperform ...

Oppenheimer recently raised the price target on Analog Devices, Inc. (NASDAQ:ADI) to $265 from $225 and kept an Outperform rating on the shares ahead of quarterly results. ADI designs ...

On Friday, Oppenheimer analysts adjusted their outlook for Braze Inc (NASDAQ: NASDAQ: BRZE), reducing the price target to $44 from a previous $51.The firm maintained its Outperform rating on the stock ...

Oppenheimer raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $19 from $17 and keeps a Perform rating on the shares.The firm sees the Delaware court’s verdict in favor of ...

The latest price target for CME Group (NASDAQ:CME) was reported by UBS on April 25, 2025. The analyst firm set a price target for $305.00 expecting CME to rise to within 12 months (a possible 5.55 ...